Streetbeat News

Stock Prices

IDXX

IDEXX Laboratories (NASDAQ:IDXX) has significantly outperformed the market, with an average annual return of 26.2% over the past 10 years. An initial investment of $1000 in IDXX a decade ago would be worth $10,115.36 today. The company's market capitalization stands at $43.48 billion, highlighting the impact of compounded returns on investment growth.

Portfolio Pulse from Benzinga Insights

December 07, 2023 | 9:00 pm

NXST

NewsNation and The CW Network attracted over 4 million viewers for the GOP Presidential primary debate, with NewsNation achieving a record 1.6 million viewers and The CW hitting its highest primetime audience since 2018. The debate was particularly successful in the New York City market. NewsNation's growth is highlighted by a 73% increase in total viewers and a 90% rise among adults 25 to 54 in weekday primetime year-to-date. The event's success is a testament to the network's growth since its inception three years ago.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 8:39 pm

DDOG

Stifel analyst Brad R. Reback upgraded Datadog Inc (NASDAQ:DDOG) to Buy from Hold and increased the price target to $140 from $98. The upgrade is based on positive customer feedback, a decline in installed-base optimization, and expectations of increased customer spending. Reback anticipates Datadog to post CY24 revenue growth of ~25%, with guidance starting at ~20%. DDOG shares are trading higher by 0.52% at $114.91.

Portfolio Pulse from Lekha Gupta

December 07, 2023 | 8:37 pm

BVS

Bioventus Inc (NASDAQ:BVS) has been upgraded by Canaccord Genuity from Hold to Buy with a price target increase to $7 from $3.66. The upgrade is based on the company's stabilization and management's strategic investments in the Exogen business, which are expected to drive future growth. The company is focusing on enhancing EBITDA and cash flows in 2023, with plans to bolster revenue growth and maintain operational margins in 2024, and expand margins to exceed 20% EBITDA by 2025-2026. Despite potential issues with interest coverage covenants and the need for a permanent CEO, the stock's low valuation at 1.4x 2024 EV/Sales suggests a high probability of continued improvement. BVS shares have risen 16.60% to $5.27.

Portfolio Pulse from Vandana Singh

December 07, 2023 | 8:35 pm

NVDA

During the fourth GOP presidential debate, candidates Nikki Haley and Ron DeSantis exchanged criticisms over their respective stances on China. The debate highlighted that if a Republican wins the 2024 election, there could be more restrictions on China, potentially impacting chipmakers. Nvidia Corp (NVDA) is mentioned as having a significant share of China's AI chip market but expects a sharp fall in China sales in Q4 due to U.S. export control rules. The Commerce Department anticipates annual updates to these restrictions.

Portfolio Pulse from Adam Eckert

December 07, 2023 | 8:34 pm

AMD

GOOGL

QQQ

US major indexes have risen due to lower-than-anticipated jobless claims. The Nasdaq, in particular, benefited from gains in AMD and Google, which have both made significant AI announcements recently.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 8:31 pm

ELV

Elevance Health (NYSE:ELV) has delivered an average annual return of 18.24% over the past 10 years, outperforming the market by 8.36% on an annualized basis. A $100 investment in ELV a decade ago would be worth $523.49 today. Elevance Health currently has a market cap of $112.38 billion.

Portfolio Pulse from Benzinga Insights

December 07, 2023 | 8:30 pm

MAR

Over the past 20 years, Marriott Intl (NASDAQ:MAR) has produced an average annual return of 11.66%, outperforming the market. A $100 investment in MAR 20 years ago would be worth $906.18 today. Marriott currently has a market cap of $61.02 billion.

Portfolio Pulse from Benzinga Insights

December 07, 2023 | 8:30 pm

WDH

Waterdrop Inc. reported disappointing Q3 financial results, with a decline in first-year insurance premiums compared to the previous year. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

December 07, 2023 | 8:28 pm

PCVX

PFE

Mizuho Securities initiated coverage on Vaxcyte Inc (PCVX), a vaccine company, with a Buy rating and a price target of $69. Vaxcyte's lead asset VAX-24, targeting pneumococcal disease, is set to enter Phase 3 in 2024. Vaxcyte's technology could disrupt Pfizer's (PFE) long-standing near monopoly in pneumococcal vaccines. Vaxcyte's vaccines, VAX-24 and VAX-31, cover more serotypes than Pfizer's current vaccines, potentially offering broader disease prevention.

Portfolio Pulse from Vandana Singh

December 07, 2023 | 8:27 pm